2020
DOI: 10.3389/fgene.2020.00081
|View full text |Cite
|
Sign up to set email alerts
|

Splicing Characterization of CLCNKB Variants in Four Patients With Type III Bartter Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
13
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
10

Relationship

4
6

Authors

Journals

citations
Cited by 20 publications
(14 citation statements)
references
References 22 publications
1
13
0
Order By: Relevance
“…Written informed consent was obtained from the proband’s parents for the publication of any potentially identifiable images or data included in this article. The method of WES was mentioned in the previous report [ 13 ]. All genetic variants were screened and listed in Table S1: Additional file 1 .…”
Section: Case Presentationmentioning
confidence: 99%
“…Written informed consent was obtained from the proband’s parents for the publication of any potentially identifiable images or data included in this article. The method of WES was mentioned in the previous report [ 13 ]. All genetic variants were screened and listed in Table S1: Additional file 1 .…”
Section: Case Presentationmentioning
confidence: 99%
“…The parents refused to do the muscle biopsy and electromyogram (EMG) but accepted the whole exome sequencing (WES). The method of WES was mentioned in our previous report [6]. To verify the mutated point, we amplified the segments carrying the mutations.…”
Section: Case Presentationmentioning
confidence: 99%
“…Generally, exonic point variants are classified as missense, synonymous, silent, or non-sense variants, and certain point variants cause abnormal precursor-mRNA (pre-mRNA) splicing, a key step in gene expression, and this has been associated to the pathogenesis of various disorders (Takeuchi et al, 2015;Gonzalez-Paredes et al, 2016;Shao et al, 2018;Han et al, 2019;Wang et al, 2020). The pre-mRNA splicing process can be changed by point variants, which disrupt canonical splice sites (5 donor site, 3 acceptor site and branch site) and polypyrimidine tract (Gonzalez-Paredes et al, 2014; or creating or deactivating sequences that regulate splicing, such as exonic splicing enhancers/silencers (ESEs/ESSs) or intronic splicing enhancers/silencers (ISEs/ISSs) (Cartegni et al, 2002;Gonzalez-Paredes et al, 2014;Takeuchi et al, 2015).…”
Section: Introductionmentioning
confidence: 99%